Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 977-981

  Begic, Damir ^a   Von Eiff, Christof ^b,d   Tsuji, Brian T ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Wyeth Pharma GmbH   (Germany)

Author keywords

Cyclic lipopeptide antibiotics; S. aureus; SCVs

Indexed keywords

DAPTOMYCIN; HEMB PROTEIN; STAPHYLOCOCCUS PROTEIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM MUTANT; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; INCUBATION TIME; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHENOTYPIC VARIATION; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; MUTATION; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 64649084205     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp069     Document Type: Article

References (12)

1. Proctor RA, van Langevelde P, Kristjansson M et al. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis 1995; 20: 95-102.
2. Proctor RA, Balwit JM, Vesga O. Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections. Infect Agents Dis 1994; 3: 302-12.
3. Kahl B, Herrmann M, Everding AS et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998; 177: 1023-9.
4. Seifert H, Wisplinghoff H, Schnabel P et al. Small colony variants of Staphylococcus aureus and pacemaker-related infection. Emerg Infect Dis 2003; 9: 1316-8.
5. von Eiff C, Becker K, Metze D et al. Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. Clin Infect Dis 2001; 32: 1643-7.
6. Tsuji BT, von Eiff C, Kelchlin PA et al. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother 2008; 52: 1533-7.
7. Jonsson I-M, von Eiff C, Proctor RA et al. Virulence of a hemB mutant displaying the phenotype of a Staphylococcus aureus small colony variant in a murine model of septic arthritis. Microb Pathog 2003; 34: 73-9.
8. Booker BM, Smith PF, Forrest A et al. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi. Antimicrob Agents Chemother 2005; 49: 1775-81.
9. Mascio CTM, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007; 51: 4255-60.
10. Baltch AL, Ritz WJ, Bopp LH et al. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob Agents Chemother 2008; 52: 1829-33.
11. Baumert N, von Eiff C, Schaaff F et al. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb Drug Resist 2002; 8: 253-60.
12. Jones T, Yeaman MR, Sakoulas G et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52: 269-78.